Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642051 | 0.97 | HPGD (0.40) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL2642855 | 0.87 | AKR1C3 (0.42) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL2646820 | 0.85 | AKR1C3 (0.41) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL2646295 | 0.85 | AKR1C3 (0.41) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL2641951 | 0.83 | CNR2 (0.41) | AKR1C3AKR1C2AKR1B10AKR1C4AKR1C1 | |
| SCHEMBL2642859 | 0.81 | HPGD (0.42) | HPGDKDM4EALDH1A1TSHR | |
| SCHEMBL2642268 | 0.78 | KCNH2 (0.46) | HPGDNPC1KDM4EALDH1A1GLA | |
| SCHEMBL2642280 | 0.76 | HPGD (0.44) | HPGDALDH1A1TSHR | |
| SCHEMBL1861372 | 0.74 | SLC6A3 (0.50) | HPGDALDH1A1 | |
| SCHEMBL2642544 | 0.74 | SLC6A3 (0.50) | HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| EP-1501815-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003095438-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | AKR1C3 761/4885AKR1C2 545/4885AKR1B10 1227/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | AKR1C3 761/4885AKR1C2 545/4885AKR1B10 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.